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Abstract
Many questions remain concerning whether, when, and how physicians order genetic tests, and
what factors are involved in their decisions. We surveyed 220 internists from two academic
medical centers about their utilization of genetic testing. Rates of genetic utilizations varied
widely by disease. Respondents were most likely to have ordered tests for Factor V Leiden
(16.8%), followed by Breast/Ovarian Cancer (15.0%). In the past 6 months, 65% had counseled
patients on genetic issues, 44% had ordered genetic tests, 38.5% had referred patients to a genetic
counselor or geneticist, and 27.5% had received ads from commercial labs for genetic testing.
Only 4.5% had tried to hide or disguise genetic information, and <2% have had patients report
genetic discrimination. Only 53.4% knew of a geneticist/genetic counselor to whom to refer
patients. Most rated their knowledge as very/somewhat poor concerning genetics (73.7%) and
guidelines for genetic testing (87.1%). Most felt needs for more training on when to order tests
(79%), and how to counsel patients (82%), interpret results (77.3%), and maintain privacy
(80.6%). Physicians were more likely to have ordered a genetic test if patients inquired about
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genetic testing (p<.001), and if physicians had a geneticist/genetic counselor to whom to refer
patients (p<.002), had referred patients to a geneticist/genetic counselor in the past 6 months, had
more comfort counseling patients about testing (p<.019), counseled patients about genetics, larger
practices (p<.032), fewer African-American patients (p<.027), and patients who had reported
genetic discrimination (p<.044). In a multiple logistic regression, ordering a genetic test was
associated with patients inquiring about testing, having referred patients to a geneticist/genetic
counselor and knowing how to order tests., These data suggest that physicians recognize their
knowledge deficits, and are interested in training. These findings have important implications for
future medical practice, research, and education.
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Genetic information can potentially enhance the prevention and treatment of numerous
disorders, but many questions exist concerning how physicians who are not geneticists view
and utilize these tests – whether, when, how, and why they order tests. Genetic testing can
potentially assist with diagnosis, guide treatment, and inform reproductive decisions.
Genetic testing is available for genes associated with a growing number of disorders, from
monogenic, highly penetrant conditions to monogenic conditions with low penetrance, and
for susceptibility testing for several more common complex disorders. Yet especially for this
last group of disorders, interpretations of genetic tests with relatively small increments in
absolute risk require sophisticated knowledge that many primary care providers may lack. In
the future, the number of genetic tests available and ordered by physicians will undoubtedly
increase. Tests are being developed for a wide variety of disorders including cancer
susceptibility, cardiac arrhythmias, seizures, immunodeficiencies, dementias, and
pharmacogenetics. With news coverage of advances in genetics, and direct-to-consumer
(DTC) marketing of tests, patients’ interest in testing will no doubt continue to grow.
Recently, the director of the National Human Genome Research Institute called for
enhancing physician use of genetic tests (Feero and Green 2011). Indeed, physicians can
strongly affect patients’ decisions about genetic testing, and play critical roles as gatekeepers
to genetic assays (Klitzman et al. 2007; Klitzman 2009). Patients may also expect providers
to have knowledge of and make appropriate referrals for genetic testing (Miller et al. 2010).
But only a limited number of studies have assessed physicians’ uses of genetic testing, and
this research suggests several problems. Physician knowledge of genetics has been low in
self-reported surveys (Chase et al. 2002; Menasha et al. 2000) and in direct assessment (Finn
et al. 2005). Only 37% regularly read articles on genetic testing (Menasha et al. 2000). For
genetic testing for cancer susceptibility, physicians have indicated needs for clinical
guidelines (89%), with many expressing concerns about insurance discrimination (81%) and
confidentiality (53%) (Freedman et al. 2003). Most (95%) believe that physician
responsibilities include counseling patients about genetic testing, but only 51% have time to
do so (Escher and Sappino 2000; Menasha et al. 2000), and among psychiatrists, fewer than
25% felt prepared to engage in counseling (Finn et al. 2005).
Nonetheless, of US primary care physicians (PCPs), one study has suggested that 60% have
ordered genetic tests, and 74% have referred a patient for genetic testing (Shields et al.
2008). Several factors may be involved in whether physicians order tests, including patient
inquiry about testing, provider assessment of the probability of a patient’s carrying a
mutation, and practice environment, with participation in an integrated health system
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associated with increased use of testing (Sifri et al. 2003). Referral for cancer susceptibility
tests was associated with patient request and physicians receiving genetic test advertising
(Wideroff et al. 2003).
Physicians may under- or over-utilize genetic tests. Of 171 physicians who had treated
Alzheimer’s disease, knowledge about the proper use of APOE and PS1 testing for both
predictive and diagnostic purposes was poor, with more than half of the physicians in many
scenarios endorsing genetic testing without appropriate justification (Chase et al. 2002).
Primary care physicians may also order BRCA testing on patients who are at low risk and
thus not appropriate for such referral (Bellcross et al. 2011; Trivers et al. 2011; Van Riel et
al. 2010; White et al. 2008). Concerning hypothetical use of genetic tests for diabetes, 79%
of PCPs and endocrinologists would be likely to order the tests, with 39% somewhat/very
likely to do so prior to “published evidence of clinical efficacy” (Grant et al. 2009). Robust
data to establish clinical utility may take several years to acquire and disseminate, and
physicians may order tests before clinical utility has been established. The possibility of
pharmacogenomics has also received attention, and 98% of physicians believed genetic
profiles may eventually impact effectiveness of pharmaceutical therapy (Stanek et al. 2009).
Yet pharmacogenomic tests for medications such as warfarin, tamoxifen, and anti-
depressants have not been widely adopted by physicians.
Questions remain about what factors (e.g., related to characteristics of physicians or their
patients) may be associated with physicians’ practices concerning genetic testing for
patients. Patient sociodemographics may play a role. Physicians serving more than 50%
minority patients were significantly less likely to have ever ordered genetic tests for 3 of 4
conditions examined (breast/ovarian cancer, colon cancer, or Huntington’s disease, but not
sickle cell), or to refer patients for genetic testing (Shields et al. 2008).
Concerns about possible genetic discrimination may also potentially affect physicians’
decisions about genetic tests, but how often physicians have observed or tried to prevent
genetic discrimination is unknown. Some critics have argued that concerns about
discrimination are exaggerated (Nowlan 2002; 2003; Wertz 2002). Hall and Rich (2000)
suggested that presymptomatic individuals experience little or no discrimination in obtaining
health insurance, but these researchers interviewed mostly individuals who worked in the
insurance industry. In a 2004–2006 a study of California physician and nurses, most
believed that fears of discrimination would deter patients from genetic testing, but most
respondents were unaware of state and federal laws prohibiting health insurance
discrimination (Lowstuter et al. 2008).
The US Genetic Information Nondiscrimination Act (GINA) was enacted in 2008, yet key
questions remain about how physicians and patients since then view the possibility of
genetic discrimination, and what, if anything, they may do as a result (e.g., whether their
concerns affect their willingness to order genetic testing, and/or efforts to disguise genetic
information). Many of the prior studies above were done over a decade ago. The amount of
genetic research and testing has mushroomed since then, and almost all of these studies were
conducted prior to the passage of GINA.
Given that rapid technological advances will offer more extensive testing and reduce its
cost, understanding internists’ and PCPs’ knowledge, attitudes, and practices regarding
genetic testing and factors involved is crucial. Clinical guidelines for utilization of genetic
testing are increasingly being developed (EGAPP Working Group 2011; Fatkin et al. 2007;
Goldman et al. 2011; Gollob et al. 2011; Hershberger et al. 2009), but it is unclear how
many physicians are aware of these guidelines, or in what specific areas they see themselves
as needing training.
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The ever-rising number of available tests, identifying genetic markers with very different
degrees of predictiveness and clinical utility, may exacerbate these problems. Yet prior
studies have each focused on testing for only one or a few disorders – particularly BRCA
1/2, with some attention to Huntington’s disease, hereditary nonpolyposis colorectal cancer,
and a few other diseases (Freedman et al. 2003; Plon et al. 2011; Prochniak et al. 2011;
Shields et al. 2008; Sifri et al. 2003; Trivers et al. 2011; Van Riel et al. 2010), or they have
not specified any diseases (Haga et al. 2011). Yet over 2,200 genetic tests exist. Hence,
critical questions also emerge as to whether physicians differentiate between different tests
in ordering practices, and if so, to what degree and how.
Thus, the purpose of this study was to explore these realms – specifically whether internists
order genetic tests on their patients, and if so, how often, and for which diseases, and what




We recruited internists who were members of departments of Internal Medicine at two
academic medical centers. Invitations to participate in the survey were sent by email with a
link to the survey instruments in July 2009 and two reminders were sent to all department
members by email. We offered a $5 gift certificate at a national coffee store chain. The
email lists contained approximately 993 and 110 addresses, respectively. Of 1103 names on
the combined lists, 220 physicians responded, yielding a conservative estimated 19.9%
response rate.
Instrumentation
The survey instrument was a 44-item questionnaire, developed by the investigators based on
past published literature and clinical experience, accessible through the online survey system
Survey Monkey (www.surveymonkey.com). We examined several domains: 1) clinicians’
self-reported knowledge of genetics and genetic testing in their area of practice; 2)
clinicians’ views and practices concerning genetic testing and genetic privacy; 3) barriers
and facilitators to appropriate clinician use of genetic tests, including clinician
characteristics (e.g., profession, specialty, number of years since completion of training, type
of practice, gender, ethnicity, religion), and patient population characteristics as reported by
these physicians (e.g., ethnicity, type of insurance coverage); and 4) self-identified needs
and implications for continuing education, clinical guidelines, and further assistance in this
area. We pilot tested the survey with five clinicians first and revised accordingly prior to
distribution.
Data Analysis
Results from the survey were transferred from the Survey Monkey platform to a database for
use in SPSS. Statistical analyses included chi-square tests for examination of categorical
variables. We also conducted a multiple logistic regression to explore which independent
variables were most associated with whether physicians had ordered a genetic test or not.
We simultaneously entered into the model variables that were significantly associated with
the outcomes in Chi square tests (as reported on Table 3). As seen on Tables 1 and 3, some
participants did not answer all questions (e.g., only 77% answered whether they had
personally had a genetic test done, or whether patients had ever reported genetic
discrimination). Hence, calculations are based on those participants who responded to each
question.
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As seen in Tables 1, 2, and 3, the sample was diverse in sex, age, ethnicity, specialties, work
settings of providers, and insurance of the patient population. Rates of ordering tests varied
widely by disease. Respondents were most likely to have ordered tests for Factor V Leiden
(16.8% n=36), followed by breast/ovarian cancer (15.0%, n=32), and hypertrophic
cardiomyopathy (8.4%, n=18). Overall, in the past 6 months, most (65%, n=115) reported
having counseled patients on genetic issues, and many respondents had ordered genetic tests
(44%, n=77), referred patients to a genetic counselor or geneticist (38.5%, n=67), and
received ads from commercial labs for genetic testing (27.5%, n=49). Only half indicated
they had “a geneticist or genetic counselor to whom you can refer patients” (53.4%, n=93),
4.5% (n=8) had taken steps to hide or disguise genetic information, and few (1.8%, n=3)
have had patients report genetic discrimination.
Over half of the respondents thought that genetic testing should be performed on more
patients in their specialty (54.4%), and that they should spend more time talking with their
patients about family histories (57.3%), but 73.7% rated their knowledge of genetics as very/
somewhat poor, and 87.1% rated their knowledge of guidelines for genetic testing as very/
somewhat poor. Most indicated a need for more training on when to order genetic testing
(79%), and how to counsel patients (82%), interpret results of genetic tests (77.3%), and
maintain genetic privacy (80.6%). Physicians favored additional genetic education on-line
(90%), in preference to grand rounds (86.3%), through the mail (i.e., printed materials sent
via the US Postal Service) (64.4%), and/or at day-long conferences (45%).
Chi-Square Analyses
As shown on Table 3, physicians were more likely to have ordered a genetic test if patients
had inquired about genetic testing (62.5% v. 24.4%, p<.001), and if physicians had larger
practices (66.7% v. 29.7%, p<.032), had fewer African-American patients (55.8% v. 37.3%,
p<.027), were comfortable counseling patients about genetic testing (62.5% v. 39.7%. p<.
019), had a geneticist or geneticist/genetic counselor to whom to refer patients (53.8% v.
30.9%, p<.002), had patients who reported genetic discrimination (100.0% v. 41.9%, p<.
044), and had knowledge of how to order and where to send tests (p<.029). There were
trends for those who ordered genetic tests to be male (51.2%, 37.6%, p<.071), have more
Caucasian patients in their practice (56.1% v. 39.0%, p<.056), and have received ads from
genetic testing laboratories (55.1% v. 39.5%, p<.062). Physicians’ decade of completion of
medical training, ethnicity, having had a genetic test, patients, concerns about genetic
privacy, having tried to hide/disguise genetic information, and perceived needs for training,
and patients’ types of insurance were all not significantly associated with ordering a genetic
test.
Binary Logistic Regression Analysis
We individually entered into a simple binary logistic regression model all of the variables
that we found in univariate analyses, as indicated above, to be significantly associated with
having ordered a genetic test. All variables found to be significant in the simple binary
logistic regression model were then simultaneously entered into a multiple binary logistic
regression model. As seen on Table 4, the multiple binary logistic regression indicated that
ordering a genetic test was associated with: patients asking about testing (p<.021; OR, 3.22;
95% CI 1.190–8.709), having referred patients to a geneticist/genetic counselor in the past 6
months (p<.01; OR, 4.5; 95% CI, 1.590–12.739), and having counseled patients on genetic
issues in the past 6 months (p<.01 OR, 4.62; 95% CI, 1.422–15.031).
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These data, the first to examine several critical areas, including rates of internists ordering
several specific genetic tests, disguising genetic information, and having patients report
discrimination, highlight several key issues. These data reveal considerable continuing self-
reported deficits in knowledge of genetic testing and guidelines – even among highly-trained
physicians in respected academic medical institutions, with innumerable opportunities for
continuing medical education. Specifically, the fact that the substantial majority (73.7% and
87.1% respectively) rated their knowledge of genetics and of guidelines for testing as very/
somewhat poor poses concerns. Moreover, large numbers who rated their knowledge of
genetics and of guidelines as very/somewhat poor (41.1% and 42.3% respectively), and were
very/somewhat uncomfortable ordering/referring for testing and counseling patients (26.1%
and 39.7% respectively), still ordered genetic tests. The fact that physicians may be ordering
tests without sufficient knowledge or comfort suggests that these tests may be ordered in
suboptimal ways, highlighting crucial needs for more targeted education. These results thus
underscore needs to substantially enhance provider understandings of genetics and
guidelines, and comfort counseling patients. Future research is also critical to probe more
fully the barriers that exist in each of these areas.
On the positive side, these physicians widely endorsed the need for more training in all four
areas probed: how to order genetic tests, counsel patients, interpret test results, and maintain
genetic privacy. Thus, amid calls for increased physician use of genetic assays (Feero and
Green 2011), the present data highlight the breadth of tests now used by at least some
physicians, but also the challenges these providers face in genetic test utilization and
interpretation.
We examined a far wider array of diseases than have prior studies of physicians.
Importantly, while prior studies have focused heavily on cancer susceptibility (particularly
BRCA and colorectal cancer [Freedman et al. 2003; Plon et al. 2011; Shields et al. 2008;
Sifri et al. 2003)], HD, and sickle cell (Shields et al. 2008), we examined several other
conditions as well and found that the most commonly ordered test was none of these, but
Factor V Leiden, which is often part of a coagulopathy evaluation. In the present study
several other tests were commonly ordered as well (e.g., hypertrophic cardiomyopathy,
cystic fibrosis, hemochromatosis, and pharmacogenetic tests), though specific physician
uses of these test results have not been examined. These data suggest internists tend to test
for a variety of treatable diseases, and that future studies should investigate a far broader
range of tests than heretofore.
The wide differences in experiences ordering genetic tests are in some ways reassuring,
given differences in disease severity, preventability, treatability, age at presentation, and
purpose of testing (diagnosis, susceptibility, or carrier status), but they suggest several
challenges for future practice and research. Efforts to understand providers’ decisions
regarding genetic assays need to account for variations in test accuracy and reliability, and in
the purpose of testing. These findings also highlight difficulties in making generalizations
about physicians’ attitudes and practices concerning genetic testing, given the wide variation
in the purpose and clinical utility of different tests. Clearly, genetic tests do not constitute
one monolithic category, but vary widely in indications (diagnostic confirmation, predictive
testing, carrier screening, and pharmacogenetic tests) and use.
The logistic regression showed that factors related to patient behavior, and physician
knowledge and behavior were most strongly associated with ordering a genetic test. Having
fewer African-American patients was not significant in the regression, possibly because it
may have been reflected in patients inquiring about tests (i.e., patients may vary in whether
they inquire about testing based on several factors, including their ethnicity). Patient report
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of genetic discrimination was also not significant in the regression, probably since few
physicians overall heard such reports. Physician comfort with genetic counseling may have
been reflected in physicians knowing how to order/where to send tests. Having a larger
practice was probably subsumed under having had patients ask about testing.
The fact that in the present study, ordering tests was associated with patient inquiry and
patients’ ethnicity raises concerns about the rational use of these assays. Ordering a genetic
test in the preceding six months was most strongly associated with patient inquiry about
genetic testing, as Sifri et al. (2003) found as well. Yet this finding is potentially troubling,
in part given the growth of marketing of genetic tests directly to consumers, even for
specific tests (Myers and Jorgensen 2005). The fact that the likelihood of a physician
ordering a genetic test may be driven in part by a patient asking about it suggests that
physicians’ decisions about ordering genetic tests may be driven by factors other than
clinical indications or clinical utility. Granted, a patient may be interested in genetic results,
even when these are not clinically actionable, simply to provide peace of mind or make
informed life-planning decisions. But some patients may ask about a test, mistakenly
thinking that they are at high risk for a disease, or believing that a negative genetic test will
mean they are not at risk at all. Hopefully, most physicians order tests as a result of
collaborative, informed decisions rather than simply to placate uninformed or misinformed
patients.
The fact that only half of physicians had a geneticist or genetic counselor to whom they
could refer patients also raises concerns. The finding that ordering of tests was significantly
associated with having such an expert available highlights the vital role that such referral
sources can play. Limitations in insurance reimbursement no doubt hamper these referrals
(i.e., genetic counseling is typically not covered by health insurance plans), underscoring
needs for changes in policy to address these impediments to care.
While Shields et al. (2008) found that providers with >50% minority patients were less
likely to order 3 of 4 tests examined, we found that providers with higher proportions of
African-American patients, but not of Hispanic patients, were less likely to have ordered a
genetic test. Hence, the specific type of minority patients a provider treats may affect rates
of testing. This finding is of concern, however, as it suggests that certain groups may be
offered potentially beneficial testing less than others, exacerbating existing health inequities.
At the same time, some minority communities are significantly more concerned about
disadvantages and potential abuses of genetic testing, which may lead to less interest and
demand among certain groups (Forman and Hall 2009; Susswein et al. 2008; Thompson et
al. 2003). We did not examine whether the rates of patients requesting genetic testing
differed between different ethnicities, or whether minority patients were offered genetic
testing and subsequently declined, but future research should do so.
Few physicians in our post-GINA survey have observed genetic discrimination or taken
steps to disguise genetic information. Less than 2% of the internist respondents had heard
reports of discrimination from their patients. Yet in 1996, 25% and 22% of members of a
variety of genetic support groups reported that their family members were refused life
insurance or health insurance, respectively (Lapham et al. 1996), and 10% of genetic clients
in Australia have reported discrimination (mostly in life insurance – in part since Australia
has national health insurance) (Taylor et al. 2007; Taylor et al. 2008). Clearly, different
types of discrimination can exist (life insurance, employment, etc.), and may affect family
members, rather than patients themselves. Internists may not inquire about these domains,
and discrimination may be subtle (Klitzman 2010), such that physicians and even patients
are not aware of it. Nonetheless, it is important that providers be aware of the possibility of
discrimination, in order to document and address it, if and when it occurs.
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Only 4.5% of the physicians in this study have taken steps to disguise genetic information.
Anecdotally, patient support groups for HD and other diseases have advocated that patients
ask doctors not to record sensitive genetic information in the medical record for patients
who are presymptomatic. Yet disguising test results, while reducing concerns about privacy,
can potentially be detrimental to medical care. The low percentage of physicians who
acknowledged disguising such information may be because this group of physicians is rarely
ordering predictive genetic testing on asymptomatic patients for genetic conditions, such as
HD, where potential discrimination may be most likely. Especially with increasing use of
electronic medical records (EMRs), future studies should continue to assess such practices
among physicians over time.
These data have several additional critical implications for future research and practice, for
instance, suggesting needs to examine advertising for commercial genetic testing (what tests
get advertised, to whom, and what these advertisements claim about the utility and potential
limitations, if any, of genetic testing). Advertising could fill an educational gap, if it
correctly informs providers about newly available genetic tests, clinical indications, and
utility. The fact that 80% of physicians wanted more training about how to maintain genetic
privacy is of importance, given the widening adoption of EMRs, which, by making
information more easily available to treaters, may affect physician and patient views about
potential discrimination. Efficient EMR systems could also potentially provide just-in-time
education about genetic testing for relevant patients through pop-up windows, identifying
patients who are candidates for genetic testing, based upon the information in the EMR.
Study Limitations
This study has several potential limitations. Compared to physicians as a whole nationally
(Runy 2009), our sample of respondents did not differ in terms of ethnicity, but did include
more women (53.3%, compared with 28.26% nationally). This difference may be due to our
focus on internists, which may include high numbers of primary care physicians who may be
more likely to be women. Indeed, since 1990, more women than men specialize in family
practice (Lambert and Holmboe, 2005), and in 2005, 49.5% of primary care physicians were
women (Tu and O’Malley, 2007). In surveying primary care physicians about BRCA
testing, Escher et al. (2000) similarly had a significantly higher response rate from women
than men (76% vs. 60% p <.008). Several other articles reporting on physician attitudes and
practices concerning genetic testing did not examine gender of respondents in any way
(Friedman et al. 2003; Grant et al. 2009; Lowstuter et al. 2008; Prochniak et al 2011; Shields
et al. 2008). Female physicians may be more personally aware of and concerned about these
issues, though in the present study gender was not significantly associated with whether
respondents had ordered genetic tests or not. Future research is clearly needed to explore
these relationships more fully
We included physicians only from academic internal medicine departments in two academic
medical centers in a single geographic region, and the response rate was 19.9%. Yet this
initial exploration of many of these issues still found several suggestive findings that can be
further investigated in future research with larger and more diverse samples. The surveys
also relied on self-reports. We did not investigate whether the tests they ordered were
appropriate for each clinical situation. Given the relatively small sample size, we also did
not explore other potential associations (e.g., whether certain groups of specialists were
more likely to order specific tests). Owing to the exploratory nature of the present study, we
did not adjust the p-values on the Chi-squared tests to account for multiple comparisons.
However, future studies can probe these issues in further detail among larger samples.
In sum, these data have critical implications for medical practice, research, policy, and
education in this rapidly expanding area. For example, they highlight several areas for future
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studies and targeted educational efforts, and needs for policies that mandate wider
reimbursement for genetic counseling.
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Year of Med School Graduation
Before 1990 36.4% (76)
After 1990 63.6% (133)
Specialty
General Medicine 19.6% (42)
Cardiology 15.4% (33)
Pulmonary/Critical Care 9.8% (21)





Infectious Disease 3.7% (8)
Family Medicine 3.7% (8)





Combination of above 14.2% (30)
MD Ethnicity
White 68.5% (146)








Klitzman et al. Page 13
Table 2
Genetic Tests Ordered in Past Six Months
Ordering Tests/Referring for Specific
Diseases
n (%)
Factor V Leiden 36 (16.8%)
Breast/Ovarian Cancer 32 (15.0%)
Hypertrophic Cardiomyopathy 18 (8.4%)
Hereditary Nonpolyposis Colorectal Cancer 17 (7.9%)
Sickle Cell 17 (7.9%)
Cystic Fibrosis 13 (6.1%)
Drug Toxicity/Pharmacogenetics 12 (5.6%)
Hereditary Hemochromatosis 12 (5.6%)
Chromosome Analysis 11 (5.1%)
Familial Adenomatous Polyposis 10 (4.7%)
Inherited Arrhythmias 10 (4.7%)
Methylenetetrahydrofolate Reductase 7 (3.3%)
Hearing Loss 4 (1.9%)
Alzheimer’s Disease 3 (1.4%)
Fragile X 2 (0.9%)
Psychiatric Illness 2 (0.9%)
Tay Sachs 2 (0.9%)
Epilepsy 1 (0.5%)
Huntington’s Disease 1 (0.5%)
Spinal Muscular Atrophy 1 (0.5%)
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Table 3
Characteristics of Internists Who Ordered a Genetic Test in Past 6 Months
Ordered Genetic Test (N v. Y)
No % (n) Yes % (n) p
MD Demographics
Gender 0.071
Male 48.8% (40) 51.2% (42)
Female 62.4% (58) 37.6% (35)
Age 0.084
20–29 62.5% (5) 37.5% (3)
30–39 52.9% (45) 47.1% (40)
40–49 74.2% (23) 25.8% (8)
50–59 37.5% (9) 62.5% (15)
60+ 60.7% (17) 39.3% (11)
Completed medical training decade NS
1960–1969 80.0% (4) 20.0% (1)
1970–1979 60.0% (9) 40.0% (6)
1980–1989 40.0% (10) 60.0% (15)
1990–1999 60.9% (14) 39.1% (9)
2000–2009 59.1% (52) 40.9% (36)
2010–2019 14.3% (1) 85.7% (6)
Still in training 50.0% (1) 50.0% (1)
Ethnicity NS
White 54.9% (67) 45.1% (55)
African-American 50.0% (3) 50.0% (3)
Asian-Pacific Islander 56.4% (22) 43.6% (17)
Hispanic 66.7% (4) 33.3% (2)
Other 80.0% (4) 20.0% (1)
Patient Demographics
Percent White 0.056
<50% 61% (75) 39% (48)
>50% 43.9% (18) 56.1% (23)
Percent African-American 0.027
<10% 44.2% (23) 55.8% (29)
>10% 62.7% (69) 37.3% (41)
Percent Asian Pacific Islander 0.081
<5% 66% (33) 34% (17)
>5% 50% (35) 50% (35)
Percent Hispanic NS
<25% 52.9% (27) 47.1% (24)
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Ordered Genetic Test (N v. Y)
No % (n) Yes % (n) p
>25% 58.3% (67) 41.7% (48)
Work setting 0.096
Hospital-based 56.5% (78) 43.5% (60)
Community-based 35.3% (6) 64.7% (11)
Combination of hospital/community-based 69.6% (16) 30.4% (7)
Number active patients in practice 0.032
Less than 100 70.3% (26) 29.7% (11)
100–499 53.4% (31) 46.6% (27)
500–1000 62.5% (20) 37.5% (12)
Over 1000 33.3% (8) 66.7% (16)
Percent of Medicaid patients NS
<25% 52.2% (35) 47.8% (32)
>25% 57.6% (53) 42.4% (39)
Percent of Medicare patients NS
<25% 53.4% (31) 46.6% (27)
>25% 57.8% (59) 42.2% (43)
Percent patients with private insurance NS
<25% 63.6% (42) 36.4% (24)
>25% 53.8% (43) 46.3% (37)
Percent patients with no insurance NS
<5% 52.3% (34) 47.7% (31)
>5% 64.2% (43) 35.8% (24)
MD/Patient Experience with Genetic Testing
Received ads from labs 0.062
No 60.5% (78) 39.5% (51)
Yes 44.9% (22) 55.1% (27)
Pts asked about genetic testing in past 6 mo. <0.001
No 75.6% (65) 24.4% (21)
Yes 37.5% (33) 62.5% (55)
How concerned about genetic privacy NS
Not very concerned 61.0% (25) 39.0% (16)
Somewhat concerned 56.2% (50) 43.8% (39)
Very concerned 53.2% (25) 46.8% (22)
Use method to hide/disguise genetic information NS
No 57.1% (96) 42.9% (72)
Yes 37.5% (3) 62.5% (5)
Pts reported genetic discrimination 0.044
No 58.1% (97) 41.9% (70)
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Ordered Genetic Test (N v. Y)
No % (n) Yes % (n) p
Yes 0% (0) 100.0% (3)
MD Experience with Genetic Testing/Counseling
Have counseled pts on genetic issues past 6 mo. <0.001
No 77.4% (48) 22.6% (14)
Yes 45.2% (52) 54.8% (63)
Have referred pts to geneticist/genetic counselor past 6 mo. <0.001
No 72.0% (77) 28.0% (30)
Yes 29.9% (20) 70.1% (47)
Have geneticist/genetic counselor for referral 0.002
No 69.1% (56) 30.9% (25)
Yes 46.2% (43) 53.8% (50)
Current practice genetic testing performed NS
More often 56.4% (53) 43.6% (41)
Less often 50.0% (6) 50.0% (6)
About the same 58.2% (39) 41.8% (28)
Spend more time on pts family histories NS
No 58.9% (43) 41.1% (30)
Yes 53.5% (53) 46.5% (46)
MD Knowledge of Genetic Testing
Knowledge of genetics NS
Very poor/Somewhat poor 58.9% (76) 41.1% (53)
Somewhat good/Good/Very good 46.5% (20) 53.5% (23)
Knowledge of guidelines pts genetic testing NS
Very poor/Somewhat poor 57.7% (86) 42.3% (63)
Somewhat good/Good/Very good 40.9% (9) 59.1% (13)
Personally had genetic test NS
No 54.7% (70) 45.3% (58)
Yes 58.1% (25) 41.9% (18)
Comfort ordering/referring testing to pts 0.073
Very uncomfortable/Somewhat uncomfortable 73.9% (34) 26.1% (12)
Somewhat comfortable/Comfortable/Very Comfortable 53.6% (15) 46.4% (13)
Comfort counseling pts on genetic testing 0.019
Very uncomfortable/Somewhat uncomfortable 60.3% (85) 39.7% (56)
Somewhat comfortable/Comfortable/Very Comfortable 37.5% (12) 62.5% (20)
MD Views on Genetic Testing Training
More training when to order genetic testing NS
No 51.4% (19) 48.6% (18)
Yes 57.4% (78) 42.6% (58)
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Ordered Genetic Test (N v. Y)
No % (n) Yes % (n) p
More training how to order genetic testing NS
No 46.7% (14) 53.3% (16)
Yes 58.0% (83) 42.0% (60)
More training counseling pts on genetic testing options NS
No 56.3% (18) 43.8% (14)
Yes 56.0% (79) 44.0% (62)
More training interpreting test results NS
No 53.8% (21) 46.2% (18)
Yes 56.7% (76) 43.3% (58)
More training maintaining genetic privacy NS
No 51.4% (18) 48.6% (17)
Yes 57.7% (79) 42.3% (58)
Genetic education day-long conference NS
No 59.6% (59) 40.4% (40)
Yes 50.0% (34) 50.0% (34)
Genetic education grand rounds NS
No 63.0% (17) 37.0% (10)
Yes 53.5% (76) 46.5% (66)
Genetic education mailed information NS
No 53.3% (32) 46.7% (28)
Yes 56.5% (61) 43.5% (47)
Genetic education online information NS
No 37.5% (6) 62.5% (10)
Yes 57.3% (86) 42.7% (64)
Knowledge of how to order and where to send tests* 0.029
One a scale of 1–5 (with 1 the least and 5 the most) 3.15 ± 1.30 2.68 ± 1.45
*Note: T-test used in this univariate analysis (Mean and standard deviation was reported for this continuous variable. The corresponding p-value
indicated by T-test is for the comparison of the two groups). Chi-squared used in all other univariate analyses in this table.
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Table 4
Predictors of Having Ordered a Genetic Test in the Past 6 Months - Multiple Logistic Regression Analysis
Predictor OR 95% CI p value
Have referred patients to a geneticist or genetic counselor 4.501 1.590–12.739 < 0.01
Have counseled patients on genetic issues 4.623 1.422–15.031 < 0.01
Patients asked about genetic testing 3.22 1.190–8.709 = 0.02
Lack knowledge on how to order and where to send tests 0.741 .465–1.180 = 0.21
Insufficient knowledge or experience about genetic tests 1.418 .801–2.509 = 0.23
Lack of clinical guidelines 0.772 .506–1.178 = 0.23
Number of patients in practice 1.283 .811–2.030 = 0.29
Comfort counseling patients 1.857 .513–6.716 = 0.35
Have a geneticist or genetic counselor for referral 0.652 .220–1.927 = 0.44
Percent of African American patients 0.984 .354–2.735 = 0.98
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